AZACONAZOLE - Результаты поиска

Австралия - английский - Department of Health (Therapeutic Goods Administration)

akm posaconazole posaconazole 100 mg modified release tablet bottle pack

pharmacor pty ltd - posaconazole, quantity: 100 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; hypromellose acetate succinate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Израиль - английский - Ministry of Health

noxafil suspension

merck sharp & dohme israel ltd - posaconazole - suspension - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses

Австралия - английский - Department of Health (Therapeutic Goods Administration)

noxafil posaconazole 100mg modified release tablets blister pack

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose acetate succinate; microcrystalline cellulose; hyprolose; silicon dioxide; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - noxafil (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older; invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. prophylaxis of invasive fungal infections, among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

noxafil posaconazole 40mg/ml oral suspension bottle

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 40 mg/ml - suspension - excipient ingredients: sodium benzoate; liquid glucose; titanium dioxide; polysorbate 80; xanthan gum; purified water; sodium citrate dihydrate; glycerol; simethicone; citric acid monohydrate; flavour - noxafil (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older; invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole.prophylaxis of invasive fungal infections, among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

noxafil posaconazole 300 mg/16.7 ml concentrated injection vial

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 300 mg - injection, concentrated - excipient ingredients: sulfobutyl betadex sodium; disodium edetate; hydrochloric acid; sodium hydroxide; water for injections - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.